The Migraine Treatment Guide Podcast
Medications, Procedures, and Surgery Explained for the management of chronic headaches, including migraine, tension headache, cluster headache, NDPH, and other headache diagnoses. Created and edited by Dr. Adam Lowenstein of the Migraine Surgery Specialty Center, this podcast covers diagnosis, medication, surgical, and non-surgical alternatives to headache medication in order to educate patients with chronic headache pain on their options for headache relief.
The Migraine Treatment Guide Podcast
CGRP Inhibitors Explained
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
A migraine “smoking gun” is almost unheard of in medical research, yet CGRP comes shockingly close. When researchers infuse this tiny peptide into people prone to migraines, it can reliably trigger a delayed attack. That single fact changes the whole conversation, so we walk through what CGRP is, how it interacts with the trigeminal system, and why neurogenic inflammation can turn normal blood vessels and nerves into a pounding, heartbeat-timed pain loop.
From there, we get practical about CGRP inhibitors for migraine prevention and acute migraine treatment. We trace the path from early gepants that worked but ran into liver toxicity, to the 2018–2020 wave of CGRP monoclonal antibodies (and safer next-generation gepants) that reshaped headache medicine. We also zoom in on what the numbers really mean in daily life: 50% responder rates, central sensitization, why “half as many migraine days” can still be a big step toward functioning, and why a small group of super responders sees life-altering results.
Then we talk about the parts that do not make it into the hype cycle: severe constipation tied to CGRP receptor biology in the gut, the cardiovascular safety question during ischemic events, who was excluded from major trials, and the steep monthly cost many patients face. Finally, we pivot to a different paradigm when chemistry fails: peripheral nerve compression, targeted nerve blocks as a screening tool, and the evidence around peripheral nerve decompression surgery for carefully selected patients, especially those with constant, unremitting daily headache patterns. If this helped you think more clearly about migraine treatment options, subscribe, share with someone who needs it, and leave a review with your biggest takeaway.
If you are suffering with headache pain despite the use of CGRP Inhibitors or other medications, learn about nerve decompression headache surgery by calling Dr. Lowenstein's Clinic at 805-969-9004 or reviewing headachesurgery.com
The Rare Migraine Smoking Gun
SPEAKER_00In the world of medical research, um, it is incredibly rare to find what you'd call a true smoking gun.
SPEAKER_01Oh, absolutely. It almost never happens like that.
SPEAKER_00Right. But imagine this if you take a person who is prone to migraines and you give them an intravenous infusion of a specific tiny protein, it will reliably trigger a massive delayed migraine attack almost every single time.
SPEAKER_01Yeah, it's not just, you know, present at the scene of the crime, it is actively causing the crime.
SPEAKER_00Aaron Powell Exactly. And today, we are hunting down that protein. We're doing a deep dive into a really comprehensive clinical document from the migraine surgery specialty center. You can actually review all their work at headache surgery.com. But our mission today is to demystify one of the biggest buzzwords in modern headache medicine right now, which is CGRP inhibitors.
SPEAKER_01And it's a massive topic. I mean, it carries incredibly high stakes for you listening because we aren't just talking about, you know, a standard tension headache that you can just sleep off with a nap.
SPEAKER_00Yeah, not at all.
SPEAKER_01Chronic migraine affects roughly three to four million Americans. These are individuals who are fundamentally losing days of their lives, they're missing work, retreating into dark rooms, totally unable to participate in their own families.
SPEAKER_00That's exactly why this deep dive feels so critical. We are going to explore the biology, the history, the real-world results, and crucially the hidden limitations of these cutting-edge drugs.
SPEAKER_01Aaron Powell Right, because there are limitations.
SPEAKER_00And if you stick around, we're going to look at a fundamentally different mechanical alternative for the people who fall through the cracks of medical therapy.
SPEAKER_01Which is a surprisingly large group of people.
SPEAKER_00It really is. But um, to understand how these new drugs work, we really have to look at the villain they're targeting first. So what
Meet CGRP And The Trigeminal System
SPEAKER_00is this protein we're infusing into people in these clinical studies?
SPEAKER_01Well, that villain is calcitonin gene-related peptide, CGRP for short.
SPEAKER_00CGRP.
SPEAKER_01Okay. It's this 37 amino acid neuropeptide that was actually first isolated back in 1982 by researchers at the Salk Institute.
SPEAKER_00Wow, 1982.
SPEAKER_01Yeah, it's been around a while. And at its core, CGRP is one of the most potent vasodilators known in human biology.
SPEAKER_00Vasodilator meaning it opens up blood vessels.
SPEAKER_01Exactly. Its primary job when released is to drastically widen your blood vessels.
SPEAKER_00So scientists find this incredibly powerful vasodilator in 1982. How long did it actually take them to figure out it was the driver behind migraines? Because I mean, for a long time the public narrative was just that migraines were some kind of, I don't know, random weather event in the brain.
SPEAKER_01Aaron Powell Right, like a stress thing or just bad luck. What's fascinating here is that the dots weren't fully connected until the 1990s. Okay. Pioneering researchers, specifically Lars Edmondson and Peter Goadsby, they firmly established CGRP as the central mediator of the migraine cascade.
SPEAKER_00So they finally mapped it out?
SPEAKER_01They did. They mapped out the anatomy and showed that CGRP is heavily concentrated in sensory neurons, specifically within the trigeminal system.
SPEAKER_00And the trigeminal system is what exactly?
SPEAKER_01It's this massive nerve network responsible for almost all the sensory input and the pain signaling in the head and the face.
SPEAKER_00Aaron Powell Okay, so when you say it's a mediator, what is actually happening physically in someone's head during an attack? Because the source document mentions uh neurogenic inflammation being triggered by this protein. But what does that actually mean for the person experiencing it?
SPEAKER_01Aaron Powell Well, think of it as a localized biological panic response.
SPEAKER_00Aaron Powell A panic response. I like that.
SPEAKER_01Aaron Powell Yeah. So when the trigeminal nerve endings are irritated, they basically dump massive amounts of CGRP into the surrounding tissue, specifically the meninges.
SPEAKER_00Aaron Powell The meninges, right. Those are the protective layers surrounding the brain.
SPEAKER_01Aaron Powell Exactly. And because CGRP is this potent vasodilator, the blood vessels rapidly expand. But um it also causes the blood vessels to become leaky.
SPEAKER_00Leaky. Wait, like fluid is leaking out of the vessels.
SPEAKER_01Aaron Powell Fluid and immune cells just rush into the surrounding tissue. So that swelling, that fluid leakage, and that intense sensitization of the nerves so that they literally throb with every single heartbeat. That is neurogenic inflammation.
SPEAKER_00Okay, let's unpack this. So is CGRP basically like an overly sensitive biological fire alarm? And when it gets pulled, it triggers a massive flood, this vasodilation and neurogenic swelling right there in the brain's trigeminal system.
SPEAKER_01Building on that analogy, it's not just a single alarm though, it's a networked security system.
SPEAKER_00Oh, interesting.
SPEAKER_01Because the CGRP receptor itself is a complex molecular structure distributed all throughout the trigeminal ganglion, the durameter, the brainstem nuclei. It's everywhere.
SPEAKER_00So it's totally systemic within that pain pathway.
SPEAKER_01Right. And because it's so widely distributed, if you can block that receptor, if you can jam the signal so the alarm can't communicate with the sprinkler system, you have the potential to interrupt the entire migraine cascade at a molecular level.
SPEAKER_00Aaron Powell Which sounds
Neurogenic Inflammation Explained Simply
SPEAKER_00like an absolute silver bullet.
SPEAKER_01Yeah.
SPEAKER_00But look, if they figure this out in the 1990s, why did it take nearly 30 years for these drugs to become the standard of care?
SPEAKER_01It's a great question.
SPEAKER_00Aaron Powell I mean, once you know the fire alarm is the problem, don't you just build a chemical to shut it off?
SPEAKER_01Aaron Powell You'd think so, but early development hit a major wall regarding how the body processes medications. The first attempts to target this therapeutically happened in the early 2000s. Scientists developed small molecule receptor antagonists, which they became known as jupants. Right. Yeah. The mechanism was perfectly sound. They blocked the CGRK receptor directly. But the early oral versions, like one called Telpage Pant, they failed dramatically around 2011.
SPEAKER_00Failed how? Like did they just not stop the migraines?
SPEAKER_01Oh no, they stopped migraines. Oh, okay. Yeah. They worked. But they caused elevated liver enzymes when dosed frequently.
SPEAKER_00Ah, litter toxicity.
SPEAKER_01Exactly. Because these were small molecules, they had to be metabolized hepatically, meaning the liver had to filter and process them.
SPEAKER_00Right, like most pools you swallow.
SPEAKER_01Yeah. And taking them daily as a preventative measure simply overwhelmed the liver's enzymes, leading to unacceptable toxicity. That essentially just shut down their use as a daily preventative drug.
SPEAKER_00Wow. It's incredible how often in medicine a drug does exactly what you want it to do in the brain, but your liver just says absolutely not.
SPEAKER_01Right. The liver is the ultimate gatekeeper.
SPEAKER_00So how did the scientific community pivot from that failure?
SPEAKER_01Well, the real breakthrough era arrived between 2018 and 2020 with a completely different vehicle for delivery: monoclonal antibodies or MABS.
SPEAKER_00Okay, MABS.
SPEAKER_01This fundamentally changed the landscape of headache medicine. You've likely seen these names in medical literature or even television commercials: Erinumab, Fremenazumab, Galcanazumab.
SPEAKER_00And there's an IV version too, right?
SPEAKER_01Yep, peptinazumab.
SPEAKER_00So why did these monoclonal antibodies bypass the liver issue? Like what makes them so different from those early Japans?
SPEAKER_01Aaron Powell It basically comes down
Why Early CGRP Drugs Failed
SPEAKER_01to molecular size and design. Monoclonal antibodies are massive proteins compared to the tiny molecules of the early Japans. Oh because they are so large, they don't cross the blood brain barrier. They remain in the peripheral circulation. And more importantly, they aren't broken down by the liver's enzyme pathways.
SPEAKER_00Aaron Powell So the liver just ignores them.
SPEAKER_01Basically. They're degraded into amino acids by the body's reticuloendothelial system over a much, much longer period.
SPEAKER_00Which means no liver toxicity.
SPEAKER_01Aaron Powell Correct. And because they have incredibly long half-lives, meaning they stay active in the bloodstream for weeks, they only need to be dosed via a subcutaneous injection once a month.
SPEAKER_00Oh, that's so much easier.
SPEAKER_01Or sometimes via infusion once a quarter. And around the same time, I should note, researchers also figured out how to refine the gip pants.
SPEAKER_00Aaron Powell Wait, they brought the Japans back?
SPEAKER_01They did. The second generation japants like Ubroge Pant and RemejaPant were formulated with excellent liver safety profiles.
SPEAKER_00Aaron Powell Okay, so the liver can handle these new ones.
SPEAKER_01Exactly. Making them viable for both acute rescue, you know, taking a pill right when you feel a migraine starting, and for prevention.
SPEAKER_00Aaron Powell I want to clarify who exactly is a candidate for this level of intervention because you don't just prescribe a monthly injectable monoclonal antibody for someone who gets like a stress headache once a year. Who are the clinical targets here?
SPEAKER_01Aaron Powell Oh, the indications are highly specific. It's based on the concept of a disabling threshold. The preventive monoclonal antibodies are designed for episodic migraine prevention, meaning patients having up to 14 headache days a month, but severe enough to cause impairment.
SPEAKER_00Up to 14 days is already half the month. It's terrible.
SPEAKER_01And they're also indicated for chronic migraine prevention, which is defined as 15 or more headache days a month. There's also an indication for episodic cluster headaches.
SPEAKER_00And what about the refined japants? If you already have these monthly injections, where do the acute rescue pills fit into the picture?
SPEAKER_01The acute japants offer a mechanism-specific option that is incredibly valuable
Monoclonal Antibodies And New Gepants
SPEAKER_01for patients who cannot tolerate older rescue medications.
SPEAKER_00Like the chipcans.
SPEAKER_01Exactly. For a long time, the standard rescue drugs were tryptans. But tryptans work by constricting blood vessels. Right. Which means they carry cardiovascular risks. If a patient has a history of heart issues, tryptans are totally contraindicated.
SPEAKER_00That makes sense. You don't want to squeeze the blood vessels of someone with heart disease.
SPEAKER_01Aaron Powell Right. Or frankly, many patients simply stop responding to tryptans over time anyway. GavPans give those patients a rescue option that blocks CGRP without causing that systemic blood vessel constriction.
SPEAKER_00Aaron Powell Okay, so we have the arsenal. We know what these drugs target and we know who they are designed to help. But I want to look at the real world application here.
SPEAKER_01Okay, let's do it.
SPEAKER_00Because in reading through the migraine surgery specialty center document, there seems to be a significant gap between the excitement of the initial clinical trials and the actual patient experience. How well do these drugs actually work?
SPEAKER_01This is where we have to view efficacy in terms of probabilities rather than guarantees.
SPEAKER_00Right.
SPEAKER_01When you look at the primary endpoints for these CGRP inhibitor trials, the gold standard metric is the 50% responder rate.
SPEAKER_00Aaron Powell Meaning the drug cuts their migraines in half.
SPEAKER_01Meaning the proportion of patients who achieve at least a 50% reduction in their total monthly migraine days across all the approved monoclonal antibodies, the data consistently shows that about 40 to 60 percent of patients hit that mark.
SPEAKER_00And what about the people not on the drug?
SPEAKER_01The placebo response in these trials is usually around 20 to 75 percent. So the true drug effect provides a meaningful, distinct benefit, but it is far from universal.
SPEAKER_00I'm gonna push back on that metric heavily though.
SPEAKER_01Go ahead.
SPEAKER_00Why is a 50% reduction considered a resounding success? I mean, if you're listening to this and you suffer from 20 severe migraine days a month, dropping to 10 still means you are spending a third of your life non-functional in a dark room.
SPEAKER_01It does sound bleak when you frame
Who These Treatments Are For
SPEAKER_01it that way. That is a very valid perspective, but it requires looking at what happens to the nervous system during chronic migraine.
SPEAKER_00Okay, explain that.
SPEAKER_01When someone is experiencing 20 migraine days a month, their nervous system is in a state of constant systemic wind-up. We call this central sensitization.
SPEAKER_00Central sensitization.
SPEAKER_01Yeah. The nerves become so hyperreactive that even light touch can feel painful.
SPEAKER_00So they are essentially living in a constant state of biological inflammation, even on the days the pain isn't at a peak.
SPEAKER_01Exactly. So dialing that down by 50% doesn't just mean erasing 10 calendar days of pain. It means reducing the baseline sensitization. Oh, I see. Often the 10 migraines the patient does still experience become far less severe. They respond much faster to rescue medications, and the post-drome, that intense hangover-like fatigue following an attack, is shortened.
SPEAKER_00That's a huge difference.
SPEAKER_01It is. A 50% reduction can fundamentally alter their disability status, changing the reality from being entirely unable to hold a job to being able to manage a relatively functional life.
SPEAKER_00Okay, that makes a lot of sense when you reframe it as turning down the volume of the entire system. And the resource does point out a smaller group of patients who experience an absolute miracle.
SPEAKER_01The super responders?
SPEAKER_00Yeah. It mentions that 5 to 15% of patients in individual trials are categorized as 100% responders.
SPEAKER_01Complete elimination of their migraines. Going to zero days of pain for a condition that was previously considered refractory is an incredible outcome for that specific 5 to 15% subset.
SPEAKER_00But blocking one of the body's most potent natural vasodilators continuously for months on end, it isn't without consequences. Let's talk about the catch.
SPEAKER_01There's always a catch.
SPEAKER_00If I'm taking these medications, what am I sacrificing elsewhere in my biology?
SPEAKER_01Well, while CGRP inhibitors are generally well tolerated compared to older daily
What Success Really Looks Like
SPEAKER_01preventatives, they certainly have a side effect profile. You see common issues like injection site reactions, redness, swelling, that sort of thing. But the systemic side effect that has garnered the most attention is severe constipation. Really? Yes. Which is particularly notable with the drug Aeronumab.
SPEAKER_00Aaron Powell Why that drug specifically? And honestly, what does a brain peptide have to do with your gut?
SPEAKER_01It goes back to the mechanism. Aeranumab specifically targets and blocks the CGRP receptor itself, whereas the other antibodies bind to the circulating peptide.
SPEAKER_00Oh, okay.
SPEAKER_01And it turns out those CGRP receptors are densely populated throughout the human gastrointestinal tract.
SPEAKER_00Oh wow.
SPEAKER_01Yeah. CGRP naturally plays a vital role in regulating gut motility, the muscle contractions that keep digestion moving along.
SPEAKER_00Okay, so when you block those receptors systematically, you effectively slow down the gut's transit time.
SPEAKER_01Exactly.
SPEAKER_00So you're turning off the fire alarm in the brain, but you're also paralyzing the conveyor belt in the stomach.
SPEAKER_01That's a strong way to put it, but mechanically, yes. The rates of clinically meaningful constipation are three to four times higher than with a placebo. Post-marketing surveillance has even reported severe cases leading to bowel obstruction requiring hospitalization.
SPEAKER_00Wow, so anyone utilizing these therapies has to aggressively monitor their GI health.
SPEAKER_01Absolutely.
SPEAKER_00But there's another major system that relies heavily on blood vessels. You mentioned earlier that CGRP is a vasodilator. What happens to the heart when you remove its ability to widen blood vessels?
SPEAKER_01This is the cardiovascular paradox of CGRP inhibitors. In a healthy resting state, locking CGRP doesn't seem to drastically alter blood pressure.
SPEAKER_00Okay, so resting is fine.
SPEAKER_01But during an ischemic event, meaning a moment when blood flow to the heart or brain is restricted, like a heart attack or a mini stroke, the body naturally upregulates CGRP.
SPEAKER_00So it floods the system with this vasodilator.
SPEAKER_01Yes, to forcefully open the coronary arteries and protect the tissue from dying.
SPEAKER_00So it's literally a built-in biological safety net for the heart.
SPEAKER_01Yes. And the theoretical concern is if you have blocked CGRP long-term with a monoclonal antibody, you have removed that protective mechanism right when the heart needs it most.
SPEAKER_00That sounds incredibly risky for anyone with a history of cardiovascular disease.
SPEAKER_01It is. It's why patients with known coronary
Constipation And The Gut Mechanism
SPEAKER_01artery disease, uncontrolled hypertension, or history of stroke were largely excluded from the pivotal clinical trials.
SPEAKER_00They weren't even tested.
SPEAKER_01No. We also see that these drugs can exacerbate conditions like Reynolds phenomenon.
SPEAKER_00What's that?
SPEAKER_01That's where the tiny blood vessels in the fingers and toes spasm in response to cold, restricting blood flow. If your body already struggles to keep those peripheral vessels open, locking a natural vasodilator is clearly counterproductive.
SPEAKER_00Right. And the fact that certain people were excluded from the trials leads us directly into a massive blind spot. Highlighted by the migraine surgery specialty center document. We're talking about patients with unremitting, constant daily headaches. Right. People who literally do not have a single pain-free minute in a month.
SPEAKER_01The most severely affected end of the spectrum.
SPEAKER_00Right. If you have 15 distinct migraines a month, a clinical trial can easily measure if you drop to seven, you hit the 50% responder rate. But if a patient is drowning in a continuous, never-ending flood of pain, how do they measure a 50% reduction? Do the trials just leave them out entirely?
SPEAKER_01Unfortunately, yes, they do. The standard endpoints of episode frequency simply do not apply if the episode never ends. Most trial protocols for these CGRP inhibitors explicitly excluded patients who presented with a headache on every single day of the month.
SPEAKER_00Which means the patients suffering the absolute most have the least amount of clinical evidence supporting the very drugs they are desperately being prescribed.
SPEAKER_01It's a huge gap in the data.
SPEAKER_00And to compound that, these drugs are incredibly expensive. The resource notes they cost anywhere from $600 to $900 a month out of pocket.
SPEAKER_01Yeah, the financial burden is real.
SPEAKER_00And, as we established earlier, 40 to 60% of people simply do not respond to them anyway.
SPEAKER_01It is a really sobering reality. For all the brilliance of the neurochemical
The Cardiovascular Safety Question
SPEAKER_01approach, it leaves a highly disabled population behind. Whether due to cost, severe GI side effects, cardiovascular risks, or simply falling into the non-responder category, thousands of patients find themselves back at square one.
SPEAKER_00Which brings us to the fundamental question. When the chemistry fails, what is left?
SPEAKER_01Exactly.
SPEAKER_00I'm stuck here. If we just spent the last 20 minutes proving that migraines are a chemical cascade driven by CGRP, how do we treat someone who doesn't respond to chemical blockers?
SPEAKER_01We move from chemistry to anatomy.
SPEAKER_00Anatomy. Okay, this is where the document really takes a turn. Instead of trying to alter the molecular signaling of the brain with massive proteins, this surgery looks for physical anatomical compression.
SPEAKER_01It operates on a completely different paradigm. The concept is that the peripheral sensory nerves, specifically the trigeminal and cervical nerve branches running through the face, the scalp, and the neck, can become physically compressed or trapped by the surrounding anatomical structures.
SPEAKER_00We're talking about bones, muscles. Yeah. What is actually trapping the nerve?
SPEAKER_01It can be tight fascial bands, enlarged muscles, bony foramina, which are the small holes in the skull that nerves pass through, or even crossing blood vessels that just pulsate against the nerve.
SPEAKER_00That sounds agonizing.
SPEAKER_01It is. This chronic physical irritation generates a persistent pain signal. That signal travels back into the brain, constantly triggering the release of CGRP, perpetuating that central sensitization we discussed earlier.
SPEAKER_00Wait, so the physical entrapment is actually causing the chemical release.
SPEAKER_01Yes.
SPEAKER_00It's like untying a physical knot or removing a clamp from a wire. It sounds almost exactly like fixing a pinched nerve or a herniated
The Trial Blind Spot And Cost
SPEAKER_00disc in your lower back, but for a migraine.
SPEAKER_01That is a highly accurate comparison. Just as a herniated disc mechanically compresses a spinal nerve and causes radiating leg pain, a tight muscle in the forehead or neck can compress a cranial nerve and trigger a radiating migraine cascade.
SPEAKER_00Makes total sense.
SPEAKER_01Releasing that compression surgically eliminates the peripheral mechanical driver of the pain.
SPEAKER_00But how can a doctor possibly know if a patient's migraine is caused by a pinch nerve versus just an overly active brain chemistry? I mean, you can't just operate on everyone and hope you find tight muscle.
SPEAKER_01You absolutely don't, and that is where the diagnostic bridge comes in. Targeted peripheral nerve blocks.
SPEAKER_00Okay, nerve blocks.
SPEAKER_01This is the critical screening tool. If a patient has failed CGRP inhibitors and other medications, a surgeon can inject a small amount of local anesthetic to temporarily numb specific trigger sites in the head and neck.
SPEAKER_00So they essentially turn off the switch locally in the tissue to see if the alarm light goes out in the brain.
SPEAKER_01Exactly that. If the nerve block temporarily completely stops or significantly reduces the pain, it proves the pain cascade is being generated at that specific anatomical site. Wow. A robust, reproducible response to a nerve block is a strong clinical predictor that releasing that specific nerve surgically will be effective.
SPEAKER_00And the efficacy data for this approach is staggering. The document states that for carefully selected patients who have failed medical therapies like tryptans and CGRP inhibitors, the published evidence shows an up to 93% success rate.
SPEAKER_01Up to 93%.
When Chemistry Fails, Try Anatomy
SPEAKER_00Up to 93%. And they define success as at least a 50% reduction in migraine frequency, duration, or intensity, with many of those patients achieving complete elimination of their pain.
SPEAKER_01It is a profound outcome. It is vital to remember we are talking about a patient population that has already failed the most advanced pharmacological options science has to offer.
SPEAKER_00And this ties back perfectly to the blind spot we talked about earlier: the constant, unremitting daily headache patients, the individuals totally excluded from the drug trials.
SPEAKER_01Yes. For patients with unremitting, constant pain, the root cause may very well not be episodic chemical release, but rather sustained mechanical compression.
SPEAKER_00Because a physical entrapment doesn't ebb and flow like a chemical cycle.
SPEAKER_01Exactly. It constantly relentlessly grinds on the nerve. For this specific population, peripheral nerve decompression surgery represents what may be the only evidence-based treatment option available that addresses the root cause rather than trying to mask the chemical symptoms.
SPEAKER_00It is
Nerve Blocks As The Screening Step
SPEAKER_00an incredible journey when you step back and look at the whole picture. I mean, we started with the isolation of the CGRP fire alarm peptide all the way back in 1982. We saw the scientific community struggle for decades through the early liver toxic Japans. Right. Eventually finding massive success with large protein monoclonal antibodies and safer next-gen japans. We look at the reality of those drugs, the life-changing relief they provide for about half of patients, which is obviously offset by the $600 to $900 monthly costs, the severe GI side effects, and the cardiovascular risks. And finally, we explored the vital anatomical alternative, peripheral nerve decompression surgery for the people who fall through the cracks of medical therapy.
SPEAKER_01It really highlights how highly individualized and multifaceted migraine treatment must be. But, you know, if we connect this to the bigger picture, there is a lingering unknown with the chemical approach that we haven't fully resolved.
SPEAKER_00Oh. What are we missing?
SPEAKER_01Well, we know CGRP is intricately involved in pain signaling, but we also know it plays a crucial physiological role in bone metabolism, in wound
Surgery Results, Unknowns, Final Disclaimer
SPEAKER_01healing, and in modulating our immune systems' responses. Okay. As millions of people begin blocking this peptide continuously every single month for decades, what unknown long-term effects might we see? Oh wow. How will our bones heal after a fracture? How will our immune systems function 10, 20, or 30 years from now? The oldest of these monoclonal antibody drugs was only approved in 2018. We simply do not have the long-term multi-decade safety data yet.
SPEAKER_00That is a massive question mark hanging over the biological chain reaction. We know how to turn off the fire alarm now, but we don't truly know what else that alarm was quietly regulating in the background. It is definitely something for you to mull over as you digest all this information. We do need to leave you with one final very important note. This deep dive is intended solely as an educational resource to help you understand the complex landscape of migraine science. It is not medical advice. All medical decisions, whether about starting medications or exploring surgical options, should be individualized and directed by a physician.
SPEAKER_01Very true.
SPEAKER_00Thanks for joining us as we explore the storm, the flood, and the science of getting your life back. We'll catch you next time.